GenesisCare’s Clinical CRO leadership team is delighted to announce we will be attending the following conferences in June 2023, in the United States:

• 2023 American Society of Clinical Oncology (ASCO) Annual Meeting – June 2-6 2023 Chicago. Booth number: 21117
• Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting – June 24-47 Chicago. Booth number: 7094
  

We can’t wait to connect with all of our valued partners and customers in person and discuss ways our teams may be able to support you to build your own therapeutic development pipeline.

GenesisCare’s Clinical CRO is an independent company within GenesisCare, providing contract clinical research services. As a global full-service CRO, we provide tailored clinical development solutions spanning the entire lifecycle of product development, with deep expertise in oncology and theranostics. Leveraging the expertise of our global physician and site network, we deliver faster, more cost-effective and efficient trials for clinical development for our customers. GenesisCare’s CRO is also home to a dedicated Imaging Research Organization (IRO), specializing in the provision of comprehensive imaging services to support oncology and theranostics research.

GenesisCare’s Contract Research Organization provides tailored bespoke services across all clinical trial phases for our customers.

One of the key benefits of our network is that we can provide customers with a fully integrated solution, comprising of our CRO, IRO, and global site network. However, as a Contract Research Organization and Imaging Research Organization, we are site and company agnostic, and also work routinely with other site research organizations, academic institutions, and hospital networks. 

Since our inception in 2018, we have become a trusted partner of choice to pharmaceutical, biotechnology, medical device sponsors, as well as leading academic institutions and tertiary hospitals.

We believe great things happen for our patients when like-minded organizations come together to innovate, collaborate, and shape the future of cancer care.

Our networked nimble approach to clinical research allows us to provide tailored solutions to meet the needs of each individual sponsor.

We are committed to operational and clinical excellence throughout all stages of drug development.